GLP-1 Weight Loss Drugs: Market Growth, Trends and Health Impacts

The market for glucagon-like peptide-1 (GLP-1) receptor agonists is experiencing rapid expansion, driven by rising obesity rates and the clinical efficacy of medications such as semaglutide, and tirzepatide. This growth is reflected in both global market projections and historical spending trends, as these drugs become central to the treatment of obesity and type 2 diabetes.

According to a report from Grand View Research, the global GLP-1 agonists weight loss drugs market was estimated at USD 13.84 billion in 2024. The market is projected to reach USD 48.84 billion by 2030, representing a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030.

Market Dominance and Distribution

North America held the largest revenue share of the GLP-1 agonists weight loss drugs market in 2024, accounting for 75.50% of the total. Within North America, the United States represented the vast majority of this share at 95.23%.

In terms of specific medications, the semaglutide (Wegovy) segment led the market with a 60.70% revenue share in 2024. The parenteral route of administration dominated the market with a 92.7% revenue share, while retail pharmacies were the leading distribution channel, accounting for 55.46% of the share in 2024.

Spending Trends and Drug Performance

Research published in JAMA Network Open, utilizing data from Symphony Health, indicates a dramatic increase in spending on GLP-1s. Between 2018 and 2023, spending on these medications rose by more than 500%, increasing from $13.7 billion to $71.7 billion when adjusted to 2023 dollars.

The growth varied significantly across different medications:

• Ozempic (semaglutide), indicated for type 2 diabetes, saw spending rise from $410 million in 2018 to $26.42 billion by 2023.
• Mounjaro, indicated for type 2 diabetes in 2022, saw spending grow from $2.51 billion in 2022 to $12.42 billion by 2023.
• Wegovy, the form of semaglutide indicated for obesity, saw spending increase from $580 million in 2021 to $6.99 billion by 2023.
• Saxenda (liraglutide), indicated for obesity, rose from $560 million in 2018 to $890 million in 2023.

Insurance Coverage and Access

Access to these medications is heavily influenced by insurance coverage, particularly in the United States. While most Medicare plans and major insurers cover GLP-1s for the treatment of type 2 diabetes, coverage for obesity and weight management is significantly more limited. In many cases, these indications are excluded from standard insurance plans.

Future demand and spending may be further driven by expanded indications and changes in how coverage is determined.

Social and Behavioral Implications

Beyond the clinical and financial data, the widespread use of GLP-1 receptor agonists has raised concerns regarding social implications. Research published on December 26, 2025, suggests that these drugs may not reduce weight stigma but could instead intensify social judgments and inequalities.

The impact of these medications is also being noted in specific populations, including college women in eating disorder recovery, who are feeling the effects of the ubiquity of GLP-1s.